STOCKHOLM – The European medical technology and in vitro diagnostics (IVD) industry is currently navigating a period of profound transformation. Against a backdrop of persistent geopolitical instability—ranging from the ongoing conflict in Ukraine to severe supply chain disruptions triggered by the closure of the Strait of Hormuz—the sector is demonstrating remarkable resilience. At the recent MedTech Forum in Stockholm, held from May 11–13, 2026, industry leaders, policymakers, and regulatory experts converged to address the dual challenges of global economic uncertainty and the complex maturation of the European Union’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).
The prevailing consensus at the forum was clear: while innovation continues at a rapid pace, the regulatory framework governing the continent must evolve to ensure Europe remains a competitive hub for life-saving technologies.
The New Frontier: The EMA’s Innovative Device Pathway Pilot
A central theme of the forum was the unveiling and initial assessment of the European Medicines Agency (EMA)-led innovative device pathway pilot. Launched on April 26, 2026, this initiative is a direct response to industry calls for a more streamlined, predictable regulatory environment.
Oliver Bisazza, CEO of MedTech Europe, set the tone during the opening day, characterizing the pilot as "exactly what our industry has been calling for." He emphasized that the initiative is not merely a bureaucratic tweak but a vital mechanism required to keep cutting-edge innovation tethered to the European market.
Weighing the Benefits: A Strategic Shift
The pilot program is designed to identify and support truly novel devices that address critical, unmet clinical needs. Flora Giorgio, head of unit at the European Commission (EC), explained the selection criteria: "With these factors determined, we ask the Notified Bodies to prioritize those technologies in their certification process, while providing every possible support within the current framework to accelerate their path to activation."
Unlike the US Food and Drug Administration (FDA), which operates a highly structured "Breakthrough" designation, the EC has opted for a flexible, voluntary pilot. This strategic choice allows regulators to gather real-world data and "codify the learning" before finalizing formal, permanent legislation. Currently, the pilot is restricted to Class III and implantable devices, with the initial application window closing on May 22, 2026.
Chronology of Regulatory Tension: From 2017 to Today
To understand the urgency expressed in Stockholm, one must look at the timeline of the EU’s regulatory journey:
- 2017: The European Union introduces the MDR and IVDR frameworks, intended to modernize safety standards and clinical oversight.
- 2022: The original target date for full implementation. Due to systemic capacity issues among Notified Bodies and industry readiness, widespread delays become inevitable.
- 2025: Persistent bottlenecks and "regulatory drag" are identified as major inhibitors of R&D investment within Europe.
- April 2026: The EMA launches the pilot program for innovative devices, marking the first major attempt to pivot toward a more collaborative regulatory model.
- February 2027 (Upcoming): New rules defining maximum timelines for Notified Bodies regarding product and Quality Management System (QMS) certifications are set to take effect, promising greater predictability.
Industry Perspectives: The Search for Sustainability
The sentiment among major industry players is one of cautious optimism tempered by a demand for systemic reform. Rita Peeters, Senior Director of Regulatory Affairs at Johnson & Johnson (J&J) MedTech, highlighted that the success of the new EMA pilot hinges on "structured dialogue."
"Our conclusions are that it is going to be particularly important to have structured dialogue with the Notified Bodies early enough," Peeters noted. She further argued that Europe must explore "reliance" mechanisms—the ability to leverage approvals granted in other jurisdictions—to prevent redundant testing and ensure European patients aren’t left behind. "If there is an approval for a device outside of Europe, how can we bring this into Europe? We need reliance, and for competitiveness, we should look at targeted incentives, such as 10-year clinical data protection, to encourage developers to prioritize the European market."
The IVD Dilemma: The Pharma Model Fallacy
Pascal Waucquez, Head of the EMEA region at bioMérieux, raised a critical concern regarding the valuation of diagnostics. He argued that the current European model for evaluating IVDs is fundamentally flawed because it mirrors the pharmaceutical industry’s framework.
"It doesn’t capture the full benefit and value of diagnostics," Waucquez stated. He cautioned that without a shift toward funding paradigms that reflect the unique nature of IVDs—which often provide cost-saving preventative data rather than acting as a therapeutic intervention—innovation in the diagnostics sector will continue to suffer.
The State of the EU IVDR: A Critical Juncture
The implementation of the IVDR remains the most contentious issue in European medtech. Market participants have long argued that the regulatory burden is causing a migration of innovation to more business-friendly jurisdictions.
Petra Zoellner, Director of Regulatory Affairs (IVDR & MDR) at MedTech Europe, provided sobering statistics. "About a third of the larger companies are saying that they prefer to place their first launch products and improvements elsewhere in the world than Europe first," she reported. This is a stark reversal from the pre-2017 landscape, where Europe was almost universally the launchpad for new medical technology.
Lena Björk, head of the medical device division at the Swedish Medical Products Agency, acknowledged the gravity of the situation. "We are in a crucial phase," Björk stated. "We all need to work together towards a predictable and sustainable regulatory framework. If these factors are not managed, the biggest risk is that we lose the credibility of the EU CE mark."
Implications: The Path Forward
The path toward a more "innovation-friendly" Europe requires a delicate balancing act. The industry is looking for three specific outcomes:
- Predictability: The upcoming February 2027 rules for Notified Body timelines are viewed as a "step in the right direction." By establishing clear expectations for certification windows, manufacturers can better allocate capital and research resources.
- Rebalancing the Regulatory Burden: As Zoellner emphasized, the goal is not to lower safety standards, but to reduce complexity. A rebalanced IVDR would ensure that small and medium-sized enterprises (SMEs) can navigate the system alongside global giants.
- Global Competitiveness: The call for "reliance" and targeted incentives highlights a growing fear of isolationism. Europe must find a way to integrate its regulatory standards with global best practices to ensure that its citizens continue to have timely access to the world’s most advanced medical devices.
As the MedTech Forum concluded, the overarching message was clear: the European medical technology sector is at an inflection point. The transition from the "long-gestating" regulations of 2017 to a more agile, pilot-driven future is underway. While the geopolitical climate remains challenging, the commitment to stabilizing the regulatory environment offers a glimmer of hope that Europe can reclaim its position as a global leader in medical innovation. The coming year, leading up to the implementation of the new certification timelines in 2027, will be the ultimate test of whether these reforms can bridge the gap between regulatory rigor and the rapid pace of technological progress.
About the Author
